Amyotrophic lateral sclerosis: Delayed disease progression in mice by treatment with a cannabinoid

Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders

Volumn 5, Issue 1, 2004, Pages 33-39

  Raman, Chandrasekaran ^a   McAllister, Sean D ^a   Rizvi, Gulrukh ^a   Patel, Sonal G ^a   Moore, Dan H ^a   Abood, Mary E ^a  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

Author keywords

9 THC; Amyotrophic lateral sclerosis; Anti excitotoxicity; Anti oxidant; Cannabinoid; Neuroprotection

Indexed keywords

6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; AMPA RECEPTOR ANTAGONIST; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR AGONIST; KAINIC ACID RECEPTOR ANTAGONIST; TETRAHYDROCANNABINOL;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG TARGETING; DRUG TOLERABILITY; FEMALE; IN VITRO STUDY; MALE; MOTOR DYSFUNCTION; MOUSE; MUSCLE EXERCISE; NERVE CELL CULTURE; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; SPINAL CORD NERVE CELL; STATISTICAL MODEL; SURVIVAL; TREMOR;

AGE FACTORS; AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; CANNABINOIDS; CELL COUNT; CELL DEATH; CELL SURVIVAL; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; EMBRYO; HUMANS; L-LACTATE DEHYDROGENASE; MICE; MICE, TRANSGENIC; MOTOR NEURONS; PIPERIDINES; PSYCHOMOTOR PERFORMANCE; PYRAZOLES; SPINAL CORD; SUPEROXIDE DISMUTASE; TERT-BUTYLHYDROPEROXIDE; TETRAHYDROCANNABINOL; TIME FACTORS;

EID: 2442484678     PISSN: 14660822     EISSN: None     Source Type: Journal    
DOI: 10.1080/14660820310016813     Document Type: Article

References (37)

1. Nicholson SJ, Witherden AS, Hafezparast M, Martin JE, Fisher EM. Mice, the motor system, and human motor neuron pathology. Mamm Genome 2000; 11: 1041-1052.
2. Brown RH, Jr. Amyotrophic lateral sclerosis: insights from genetics. Arch Neurol 1997; 54: 1246-1250.
3. Cleveland DW, Rothstein JD. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat Rev Neurosci 2001; 2: 806-819.
4. Ludolph AC, Meyer T, Riepe MW. The role of excitotoxicity in ALS:what is the evidence? J Neurol 2000; 247: 17-16.
5. Robberecht W. Oxidative stress in amyotrophic lateral sclerosis. J Neurol 2000; 247: 11-6.
6. Carter GT, Rosen BS. Marijuana in the management of amyotrophic lateral sclerosis. Am J Hosp Palliat Care 2001; 18: 264-270.
7. Hampson A, Grimaldi M, Axelrod J, Wink D. Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci U S A 1998; 95: 8268-8273.
8. Shen M, Thayer S. Delta9-Tetrahydrocannabinol acts as a partial agonist to modulate glutamatergic synaptic transmission between rat hippocampal neurons in culture. Mol Pharmacol 1999; 55: 8-13.
9. van der Stelt M, Veldhuis WB, Bar PR, Veldink GA, Vliegenthart JF, Nicolay K. Neuroprotection by Delta9-tetrahydrocannabinol, the main active compound in marijuana, against ouabain-induced in vivo excitotoxicity. J Neurosci 2001; 21: 6475-6479.
10. Abood ME, Rizvi G, Sallapudi N, McAllister SD. Activation of the CB(1) cannabinoid receptor protects cultured mouse spinal neurons against excitotoxicity. Neurosci Lett 2001; 309: 197-201.
11. Baker D, Pryce G, Croxford J et al. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 2000; 404: 84-87.
12. Baker D, Pryce G, Croxford JL et al. Endocannabinoids control spasticity in a multiple sclerosis model. Faseb J 2001; 15: 300-302.
13. Gelinas D, Miller R, Abood M. A pilot study of safety and tolerability of Delta 9-THC (Marinol) treatment for ALS. Amyotrophic Later Scler & Motor Neuron Disord 2002; 3: 23.
14. Rosen D, Siddique T, Patterson D et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993; 362: 59-62.
15. Gurney M, Pu H, Chiu A et al. Motor neuron degeneration in mice that express a human Cu/Zn superoxide dismutase mutation. Science 1994; 264: 1772-1775.
16. Bruijn L, Becher M, Lee M et al. ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron 1997; 18: 327-338.
17. Wong P, Pardo C, Borchelt D et al. An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron 1995; 14: 1105-1116.
18. Gurney ME, Cutting FB, Zhai P et al. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol 1996; 39: 147-157.
19. Zhu S, Stavrovskaya IG, Drozda M et al. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 2002; 417: 74-78.
20. Klivenyi P, Ferrante RJ, Matthews RT et al. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat Med 1999; 5: 347-350.
21. 9-THC without alteration of cannabinoid receptor binding or mRNA levels in whole brain. Pharmacol Biochem Behav 1993; 46: 575-579.
22. Carriedo S, Yin H, Weiss J. Motor neurons are selectively vulnerable to AMPA/kainate receptor-mediated injury in vitro. J Neurosci 1996; 16: 4069-4079.
23. Abe K, Saito H. Characterization of t-butyl hydroperoxide toxicity in cultured rat cortical neurons and astrocytes. Pharmacol Toxicol 1998; 83: 40-46.
24. Pinheiro JC, Bates DM. Mixed-Effects Models in S and S-PLUS. New York: Springer; 2000.
25. Kaplan E, Meier P. Non-parametric estimation from incomplete observations. J Amer Statist Assoc 1958; 53: 457-481.
26. Wallace MJ, Wiley JL, Martin BR, DeLorenzo RJ. Assessment of the role of CB1 receptors in cannabinoid anticonvulsant effects. Eur J Pharmacol 2001; 428: 51-57.
27. Li M, Ona VO, Guegan C et al. Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. Science 2000; 288: 335-339.
28. Griffin G, Wray E, Tao Q et al. Evaluation of the cannabinoid CB2 receptor-selective antagonist, SR144528: further evidence for cannabinoid CB2 receptor absence in the rat central nervous system. Eur J Pharmacol 1999; 377: 117-125.
29. Nagayama T, Sinor A, Simon R et al. Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J Neurosci 1999; 19: 2987-2995.
30. Marsicano G, Moosmann B, Hermann H, Lutz B, Behl C. Neuroprotective properties of cannabinoids against oxidative stress: role of the cannabinoid receptor CB1. J Neurochem 2002; 80: 448-456.
31. Eshhar N, Striem S, Kohen R, Tirosh O, Biegon A. Neuro-protective and antioxidant activities of HU-211, a novel NMDA receptor antagonist. Eur J Pharmacol 1995; 283: 19-29.
32. Consroe P, Musty R, Tilley W, Pertwee R. The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur Neurol 1996; 38: 44-48.
33. Malec J, Harvey R, Cayner J. Cannabis effect on spasticity in spinal cord injury. Arch Phys Med Rehabil 1982; 63: 116-118.
34. Voth E, Schwartz R. Medicinal applications of Delta-9-tetrahydrocannabinol and marijuana. Ann Intern Med 1997; 126: 791-798.
35. Louvel E, Hugon J, Doble A. Therapeutic advances in amyotrophic lateral sclerosis. Trends Pharmacol Sci 1997; 18: 196-203.
36. Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group [see comments]. N Engl J Med 1994; 330: 585-591.
37. Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev 2000; 2: CD001447.